Skip to Main Content

Efficacy and Safety of Nefecon in Patients w/ Primary IgA (Immunoglobulin A) Nephropathy (Nefigard)

Conditions

Diseases of the Kidney & Urinary Tract

Phase III

What is the purpose of this trial?

The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment with renin-angiotensin system (RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).

  • Trial with
    Calliditas AB
  • Start Date
    04/15/2019
  • End Date
    10/30/2020
Trial Image

For more information about this study, contact:

Lauren Liberti

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/05/2019
  • Study HIC
    #2000024668